

Special Issue

New Insights in Esophageal Cancer Diagnosis and Treatment

Message from the Guest Editor

Esophageal cancer represents the 7th leading cancer worldwide, with the adenocarcinoma subtype rising in the Western Hemisphere. Unfortunately, the 5-year survival rate for this group of patients is approximately 20%. Targeted screening using various modalities and risk stratification of precursor lesions may help facilitate early diagnosis. Improvements in endoscopic treatments to preserve structural and functional integrity with early lesions and palliation in advanced disease are being undertaken. It is hoped that biomarker-driven systemic therapies will improve survival in advanced diseases. This Special Issue reflects the ongoing efforts to make esophageal adenocarcinoma a promptly diagnosable and potentially curable disease.

Guest Editor

Dr. Virendra Joshi
School of Medicine, Emory University, Atlanta, GA 30322, USA

Deadline for manuscript submissions

27 November 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/257791

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)